SINGAPORE eDEVELOPMENT LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 200916763W)
FORMATION OF NEW SUBSIDIARIES
The Board of Directors (the “Board”) of Singapore eDevelopment Limited (the “Company” and together with its subsidiaries, the “Group”) wishes to announce that:
(1) The following companies were incorporated as subsidiaries of the Company:
(a) A wholly-owned subsidiary in Singapore on 10 April 2017 named “Global Lite Food Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. Global Lite Food Pte. Ltd. shall be principally engaged in investment holding.
(b) A wholly-owned subsidiary in Singapore on 10 April 2017 named “SeD Global Management Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SeD Global Management Pte. Ltd. shall be principally engaged in investment holding.
(c) A wholly-owned subsidiary in Singapore on 10 April 2017 named “SeD Health Solution Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SeD Health Solution Pte. Ltd. shall be principally engaged in investment holding.
(d) A wholly-owned subsidiary in Singapore on 10 April 2017 named “SeD Medical Solution Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SeD Medical Solution Pte. Ltd. shall be principally engaged in investment holding.
(2) The following companies were incorporated as subsidiaries of Singapore BioMedical Pte. Ltd., a wholly-owned subsidiary of the Company:
(a) A wholly-owned subsidiary in Singapore on 19 April 2017 named “SingLife Regenerate Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SingLife Regenerate Pte. Ltd. shall be principally engaged in investment holding.
(b) A wholly-owned subsidiary in Nevada, USA on 29 March 2017 named “SeD BioLife International Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. SeD BioLife International Inc shall be principally engaged in investment holding.
(c) A wholly-owned subsidiary in Nevada, USA on 18 April 2017 named “Global BioMedical Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. Global BioMedical Inc shall be principally engaged in investment holding.
(3) The following company was incorporated as a subsidiary of SeD BioLife International Inc:
(a) A wholly-owned subsidiary in Nevada, USA on 13 March 2017 named “SeD BioMedical International Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. SeD BioMedical International Inc shall be principally engaged in investment holding.
2
(4) The following company was incorporated as a subsidiary of Global BioMedical Inc:
(a) A non wholly-owned subsidiary in Nevada, USA on 14 April 2017 named “Global BioLife Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. Global BioLife Inc shall be principally engaged in investment holding. Global BioMedical Inc holds 80% of the issued and paid up share capital of Global BioLife Inc. The remaining shareholding in Global BioLife Inc is held by GRDG Sciences LLC (“GRDGS”) and Holista CollTech Limited (“Holista”) in equal proportions of 10% each.
A flowchart of the new companies being incorporated is enclosed for your easy reference:
3
The incorporation of Global Lite Food Pte. Ltd., SeD Global Management Pte. Ltd., SeD Health Solution Pte. Ltd., SeD Medical Solution Pte. Ltd., SingLife Regenerate Pte. Ltd., SeD BioMedical International Inc, SeD BioLife International Inc, Global BioMedical Inc and Global BioLife Inc were funded through internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Company for the financial year ending 31 December 2017.
http://sed.com.sg/content/uploads/2017/05/SeD...5.2017.pdf
(Incorporated in the Republic of Singapore)
(Company Registration No. 200916763W)
FORMATION OF NEW SUBSIDIARIES
The Board of Directors (the “Board”) of Singapore eDevelopment Limited (the “Company” and together with its subsidiaries, the “Group”) wishes to announce that:
(1) The following companies were incorporated as subsidiaries of the Company:
(a) A wholly-owned subsidiary in Singapore on 10 April 2017 named “Global Lite Food Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. Global Lite Food Pte. Ltd. shall be principally engaged in investment holding.
(b) A wholly-owned subsidiary in Singapore on 10 April 2017 named “SeD Global Management Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SeD Global Management Pte. Ltd. shall be principally engaged in investment holding.
(c) A wholly-owned subsidiary in Singapore on 10 April 2017 named “SeD Health Solution Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SeD Health Solution Pte. Ltd. shall be principally engaged in investment holding.
(d) A wholly-owned subsidiary in Singapore on 10 April 2017 named “SeD Medical Solution Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SeD Medical Solution Pte. Ltd. shall be principally engaged in investment holding.
(2) The following companies were incorporated as subsidiaries of Singapore BioMedical Pte. Ltd., a wholly-owned subsidiary of the Company:
(a) A wholly-owned subsidiary in Singapore on 19 April 2017 named “SingLife Regenerate Pte. Ltd.” with an issued and paid-up capital of S$2.00 comprising 2 ordinary shares. SingLife Regenerate Pte. Ltd. shall be principally engaged in investment holding.
(b) A wholly-owned subsidiary in Nevada, USA on 29 March 2017 named “SeD BioLife International Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. SeD BioLife International Inc shall be principally engaged in investment holding.
(c) A wholly-owned subsidiary in Nevada, USA on 18 April 2017 named “Global BioMedical Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. Global BioMedical Inc shall be principally engaged in investment holding.
(3) The following company was incorporated as a subsidiary of SeD BioLife International Inc:
(a) A wholly-owned subsidiary in Nevada, USA on 13 March 2017 named “SeD BioMedical International Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. SeD BioMedical International Inc shall be principally engaged in investment holding.
2
(4) The following company was incorporated as a subsidiary of Global BioMedical Inc:
(a) A non wholly-owned subsidiary in Nevada, USA on 14 April 2017 named “Global BioLife Inc” with an issued and paid-up capital of US$1.00 comprising 1,000 ordinary shares. Global BioLife Inc shall be principally engaged in investment holding. Global BioMedical Inc holds 80% of the issued and paid up share capital of Global BioLife Inc. The remaining shareholding in Global BioLife Inc is held by GRDG Sciences LLC (“GRDGS”) and Holista CollTech Limited (“Holista”) in equal proportions of 10% each.
A flowchart of the new companies being incorporated is enclosed for your easy reference:
3
The incorporation of Global Lite Food Pte. Ltd., SeD Global Management Pte. Ltd., SeD Health Solution Pte. Ltd., SeD Medical Solution Pte. Ltd., SingLife Regenerate Pte. Ltd., SeD BioMedical International Inc, SeD BioLife International Inc, Global BioMedical Inc and Global BioLife Inc were funded through internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Company for the financial year ending 31 December 2017.
http://sed.com.sg/content/uploads/2017/05/SeD...5.2017.pdf
5
